Sarepta to Present New Duchenne Data at WMS 2026, Including Late-Breaking Efficacy Results

  • Sarepta Therapeutics will present new data on delandistrogene moxeparvovec (ELEVIDYS) at the 2026 World Muscle Society Annual Congress, including a late-breaking poster on efficacy and safety in older ambulatory Duchenne patients (aged 8-12).
  • Presentations cover functional and safety outcomes up to 3 years post-infusion, micro-dystrophin expression in young patients, and pooled safety analysis from Phase 1-3 trials.
  • Additional data includes efficacy and safety comparisons of golodirsen and casimersen with placebo in Duchenne muscular dystrophy.
  • The congress takes place September 29 - October 3, 2026, in Hiroshima, Japan.

Sarepta's presentations at the WMS 2026 Congress come at a critical time for the company as it seeks to solidify its position in the Duchenne muscular dystrophy market. The focus on long-term efficacy and safety data will be key in differentiating ELEVIDYS from competitors and potentially expanding its patient population. The broader industry is watching closely as gene therapy advancements continue to reshape the treatment landscape for rare diseases.

Clinical Efficacy
How the late-breaking data on older ambulatory patients will impact the therapeutic potential of ELEVIDYS.
Long-Term Safety
Whether the pooled safety analysis from Phase 1-3 trials will reveal any new safety concerns or reinforce existing ones.
Market Positioning
The pace at which Sarepta can leverage these data presentations to strengthen its leadership in Duchenne muscular dystrophy treatments.